Objective: To describe the design of the phase 3 TEMPO program that will evaluate the efficacy, safety, and tolerability of once-daily (QD) tavapadon in early-stage and advanced Parkinson’s disease (PD).
Objective: To describe the design of the phase 3 TEMPO program that will evaluate the efficacy, safety, and tolerability of once-daily (QD) tavapadon in early-stage and advanced Parkinson’s disease (PD).
You are now leaving cerevel.com, a website provided by Cerevel Therapeutics. The content displayed on external websites is not controlled by Cerevel, and Cerevel assumes no responsibility for the information or statements on external websites.